Pharma manufacturing news in brief
pharmafile | January 14, 2013 | News story | Manufacturing and Production |Â Â ADMA, Biotest, Catalent, Emerson, Nanocarrier, Orient Europharma, UCBÂ
Facility news from Orient Europharma/NanoCarrier, Catalent and China Biologic, plus new contracts for Emerson Process Management and Biotest Pharma.
Taiwan’s Orient Europharma (OEP) and partner NanoCarrier of Japan have said they will invest $24 million in a new plant for the production of cancer drugs at the Central Taiwan Science Park. The two firms are collaborating on the development of chemotherapy candidate Nanoplatin (liposomal cisplatin), which has reached Phase II testing. The agreement gives OEP a non-exclusive manufacturing license to the drug in addition to its existing development and marketing rights.
ADMA Biologics has entered into a long-term manufacturing, supply and license agreement with Biotest Pharmaceuticals for the supply of its lead immune globulin product candidate RI-002 for treating primary immune deficiency. Under the terms of the 10-year deal Biotest will manufacture RI-002, while its parent company Biotest AG also gains marketing rights to the drug in Europe and certain Middle East and North Africa (MENA) countries. Earlier this month ADMA said it had secured a $6 million loan to take RI-002 into Phase III testing.
Catalent Pharma Solutions has said it will invest $20 million to expand its manufacturing capacity for pressurised metered dose inhalers (pMDIs) at its facility in Research Triangle Park, North Carolina. The company said the expansion comes on top of the introduction of scalable processes for micro-dosing inhalation powder formulations and the recent commissioning of a new nasal filling suite, and “positions [it] as a world leader in supporting inhaled products”.
Plasma specialist China Biologic has said it may have to delay starting construction of a new manufacturing facility in Guizhou while it waits for the government to approve land use rights. The company said earlier it hoped to start work on the Guizhou Taibang plant at the end of 2012 and bring it online in mid-2014China Biologic has said it expects to halt production at its existing production facility in Guizhou by the end of 2013, now that more stringent Good Manufacturing Practice (GMP) standard are coming into effect in China.
UCB has awarded a $6.1 million contract to Emerson Process Management to automate its new biopharmaceutical production centre in Bulle, Switzerland. The firm is spending $228 million on the 20,000 sq. m. facility, which on completion will be the main production unit for UCB’s fast-growing rheumatoid arthritis and Crohn’s disease treatment Cimzia (certolizumab pegol).
Phil Taylor
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
